uPA、uPAR、PAI-1血浆含量与卵巢恶性肿瘤的相关性研究

目的：探讨尿激酶型纤溶酶原激活物（uPA）及其受体（uPAR）和抑制剂（PAI-1）血浆含量与卵巢恶性肿瘤之间的关系。方法：收集52例卵巢恶性肿瘤患者血液标本，以30例健康人作对照，用ELISA法分别检测uPA、uPAR和PAI-1的含量。结果：uPA、uPAR在卵巢恶性肿瘤各期之间均有极显著性差异（P〈0．01），PAI-1在卵巢恶性肿瘤FIGO Ⅰ～Ⅲ期的含量逐渐升高，但在FIG0Ⅳ期时显著下降（P〈0．05）。患者组uPA、uPAR、PAI-1均较对照组升高，差异极显著（P〈0．01）。结论uPA、uPAR在卵巢恶性肿瘤患者可作为预后的判断指标，PAI-1与卵巢恶性肿瘤的分期有一定的相关性。

Association of plasma level of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor (uPAR),and plasminogen activator inhibitors type 1 with ovarian cancer

Objective To investigate the relationship between plasma level of urokinase-type plasminogen activator(uPA),urokinase-type plasminogen activator receptor(uPAR)and plasminogen activator inhibitor type 1(PAI-1)and ovarian cancer.Method The concentration of uPA,uPAR and PAI-1 in 52 patients with ovarian cancer and 30 healthy subjects were simultaneously determined by ELISA.Results There were significant differences for uPA and uPAR in different grades of the patients with ovarian cancer(P<0.01).However,there was no significant difference for PAI-1 in ovarian cancer patients with different grades.There were significant differences in PAI-1,uPA,uPAR between the patients with ovarian cancer and healthy subjects(P<0.01).Conclusion uPA,uPAR and PAI-1 may play important roles and be used as the parameters for progression and reimplantation of ovarian malignant cancer cells.